Lexicon Pharmaceuticals, Inc.
NASDAQ:LXRXBiotechnology
-$0.05 today
- Market cap
- $765.80M
- Beta
- 1.07
- P/E (TTM)
- -30.5
- EPS (TTM)
- -$0.07
Volume 2.02M
Average 2.48M
LXRX Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Lexicon Pharmaceuticals, Inc.NASDAQ: LXRX
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow declines year over year
Q1 FY2026 free cash flow of $14.73M (cash outflow) fell 66.4% year over year, ahead of the -77.0% change in trailing-twelve-month free cash flow. Sequentially, it fell 14.5% from the prior quarter. Over 3 fiscal years it compounded at -9.0% a year.
Context
- Free cash flow amounted to 136.2% of revenue in FY2025, down 442.3 pp from a year earlier.
- Free cash flow grew in size in 2 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -66.4% holds above the trailing-twelve-month pace of -77.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (67.85M) USD
- Year-over-year change
- +62.3%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (67.85M) | +62.3% |
| FY2024 | 2024-12-31 | (179.81M) | -10.7% |
| FY2023 | 2023-12-31 | (162.37M) | -80.1% |
| FY2022 | 2022-12-31 | (90.18M) | -2.2% |
| FY2021 | 2021-12-31 | (88.24M) | — |
Free Cash Flow vs competitors
How LXRX compares with its peers on the latest reported figures
- LXRX's LTM Mar 2026 free cash flow of $38.8M is the 9th largest of the 11 companies compared; the peer median is $51.82M.
- Its year-over-year change of -77.0% is the 10th highest of 11, against a peer median of +17.3%.
- Free cash flow amounts to 55.7% of revenue for LXRX, versus a peer median of 35.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $616.26M | +103.6% | +2.8% | 64.2% | |
| LTM Jun 2026 | $357.11M | +2165.8% | — | 38.0% | |
| LTM Jun 2026 | $332.56M | -148.8% | — | 33.0% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $193.4M | -3.0% | +21.4% | — |
| LTM Mar 2026 | $111.36M | -4.5% | +13.9% | — | |
| LTM Mar 2026 | $79.27M | +124.4% | — | 26.4% | |
| LTM Sep 2026 | $61.69M | +40.1% | +14.1% | — | |
| LTM Mar 2026 | $41.95M | -15.4% | -12.2% | 589.1% | |
| LTM Mar 2026 | $38.8M | -77.0% | -9.0% | 55.7% | |
| LTM Mar 2026 | $31.09M | +37.5% | +35.9% | — | |
| LTM Mar 2026 | $12.72M | -41.7% | — | 3.5% | |
| Peer median (excluding LXRX) | $51.82M | +17.3% | +14.0% | 35.5% | |
Competitors are the stored peer set for LXRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (87.76M) | (101.94M) | (177.12M) | (200.4M) | (50.34M) |
| Depreciation & Amortization | 292K | 427K | 554K | 534K | 621K |
| Deferred Income Tax | 49K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 10.58M | 11.52M | 14.34M | 13.5M | 12.52M |
| Change in Working Capital | (10.23M) | 402K | 2.66M | 14.24M | (26.89M) |
| Accounts Receivables | 381K | (14K) | (982K) | (2.46M) | 1.09M |
| Inventory | 0 | 0 | (381K) | 150K | (50K) |
| Accounts Payables | (14.16M) | 76K | 6.45M | 14.8M | (30.22M) |
| Other Working Capital | 3.55M | 340K | (2.43M) | 1.75M | 2.29M |
| Other Non-Cash Items | 54K | 744K | (2.33M) | (6.65M) | (3.75M) |
| Operating Cash Flow | (87.02M) | (88.85M) | (161.9M) | (178.78M) | (67.85M) |
| Capital Expenditures | (1.22M) | (1.33M) | (470K) | (1.03M) | 0 |
| Acquisitions (Net) | (3.33M) | 69.75M | 0 | 0 | 0 |
| Purchases of Investments | (34.26M) | (133.95M) | (223.34M) | (338.05M) | (143.55M) |
| Sales of Investments | 37.59M | 64.2M | 173.87M | 314.4M | 252.86M |
| Other Investing Activities | 3.33M | (69.75M) | 0 | 9.31M | 3.71M |
| Investing Cash Flow | 2.11M | (71.08M) | (49.94M) | (15.38M) | 113.02M |
| Debt Repayment | (11.7M) | 48.87M | 49.96M | 0 | (48M) |
| Common Stock Issued | 37.08M | 94.21M | 138.82M | 64K | 73K |
| Common Stock Repurchased | (2.68M) | (864K) | (824K) | (1.73M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 94.21M | 0 | (1.24M) | (572K) |
| Financing Cash Flow | 22.71M | 142.21M | 187.96M | 238.35M | (48.5M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (62.2M) | (17.72M) | (23.88M) | 44.19M | (3.33M) |
| Free Cash Flow | (88.24M) | (90.18M) | (162.37M) | (179.81M) | (67.85M) |
Lexicon Pharmaceuticals, Inc.
NASDAQ:LXRX
Intrinsic Alpha fair value
Locked
Current Price
$1.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.